AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by ...

PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance ...

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that's been standard treatment for more than a decade.

Daiichi Sankyo has announced the first subject dosing in the Phase III DESTINYEndometrial01 trial of Enhertu (trastuzumab ...

In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses results from an interim analysis of the DESTINY-Breast09 trial, which were presented at ASCO Annual Meeting.The ...

Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

Pāpāmoa retiree Marion Henriksen was meant to be travelling in Germany and Austria with a friend. Instead, she had to cancel ...

Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated a median overall survival of 14.7 months Results reinforce second-line use of ENHERTU globally in this setting ENHERTU is a specifically ...

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE: AZN) have released detailed Phase III results that could help position their HER2-targeting drug Enhertu (trastuzumab deruxtecan) as the second-line ...